Search Results - Jones-Leone, Angela R.

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

    The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis by Wilkinson, Christel, Henderson, Robert B, Jones-Leone, Angela R, Flint, Shaun M, Lennon, Mark, Levy, Roger A, Ji, Beulah, Bass, Damon L, Roth, David

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT

    MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab... by Sada, Kenei, Kurita, Noriaki, Noma, Hisashi, Matsuki, Taizo, Quasny, Holly, Levy, Roger A, Jones-Leone, Angela R, Gairy, Kerry, Yajima, Nobuyuki

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    Drug-Drug Interaction Between Phosphate Binders and Daprodustat in ASCEND-D: SA-PO255

    Drug-Drug Interaction Between Phosphate Binders and Daprodustat in ASCEND-D: SA-PO255 by Stankus, Nicole S., Meadowcroft, Amy M., Bhatt, Nisha, Jones-Leone, Angela R., Bhatt, Purav R., Shannon, Jennifer, Singh, Ajay K.

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Hemoglobin Stability in the ASCEND-TD Trial: SA-OR53

    Hemoglobin Stability in the ASCEND-TD Trial: SA-OR53 by Acharya, Anjali, Rastogi, Anjay, Jha, Vivekanand, Singh, Ajay K., Meadowcroft, Amy M., Bhatt, Purav R., Jones-Leone, Angela R., Shannon, Jennifer

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN): SA-PO881

    Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN): SA-PO881 by Rovin, Brad H., Furie, Richard, Malvar, Ana, Aranow, Cynthia, Pego-Reigosa, José M., Zakharova, Elena, Schwarting, Andreas, Jones-Leone, Angela R., Gilbride, Jennifer A., Ji, Beulah, Roth, David A., Curtis, Paula S., Maurik, André van

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN): SA-OR32

    Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN): SA-OR32 by Anders, Hans J., Rovin, Brad H., Zhao, Ming Hui, Malvar, Ana, Hiromura, Keiju, Jones-Leone, Angela R., González-Rivera, Tania, Gilbride, Jennifer A., Madan, Anuradha, Green, Yulia, Roth, David A.

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    1.4 Harmony 8: Once Weekly (QW) GLP1 Agonist Albiglutide (Albi) vs. Sitagliptin (Sita) in Type 2 Diabetes (T2D) Pts With Renal Impairment (RI): Week 26 Results (68-OR)

    1.4 Harmony 8: Once Weekly (QW) GLP1 Agonist Albiglutide (Albi) vs. Sitagliptin (Sita) in Type 2 Diabetes (T2D) Pts With Renal Impairment (RI): Week 26 Results (68-OR) by Leiter, Lawrence A., Carr, Molly C., Stewart, Murray, Jones-Leone, Angela R., Yang, Fred, Handelsman, Yehuda

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

    Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with typ... by Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc

    Published in Diabetologia
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program

    Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program by Davidson, Jaime A., Jones-Leone, Angela, Wilson, Timothy H., Nino, Antonio, Forero-Schwanhaeuser, Sergio, Reinhardt, Rickey R.

    Published in Postgraduate medicine
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: